Future outlook

Our ambition is to create the gold standard in continuous processing.

The market for biosimilars will grow very rapidly in the coming 10 years. At the same time the market will become more generic thus making differentiation in pricing extremely important.​

Developing our biosimilar portfolio and the 3C technology

Next to the development of a broader portfolio of selected biosimilars on our continuous process we will scale-up and further commercialize our technology platform, including licensing outside of the biosimilar field. 

Once continuous becomes more mainstream with high titer cell lines, transfer of early stage innovator batch processes into continuous process product developments can start.

Antibody

Interested to work with us?

Join our team
Antibody